Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report

INTRODUCTION: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for first line treatment for metastatic renal cell carcinoma and imatinib-resistant metastatic gastrointestinal stromal tumors. Sunitinib administration can cause myelosuppression resulting in neutropenia and thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Zia, George, Mathew K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599754/
https://www.ncbi.nlm.nih.gov/pubmed/23442444
http://dx.doi.org/10.1186/1752-1947-7-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599754/
https://www.ncbi.nlm.nih.gov/pubmed/23442444
http://dx.doi.org/10.1186/1752-1947-7-54

Ejemplares similares